60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.635
+0.085 (5.48%)
Oct 9, 2025, 4:00 PM EDT - Market closed
SXTP Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$328,165
Profits / Employee
-$2,769,166
Market Cap
6.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SXTP News
- 23 hours ago - 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study - GlobeNewsWire
- 5 weeks ago - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 7 weeks ago - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion - GlobeNewsWire